Heart failure (HF) is a significant cause of death and the leading cause of hospitalization in patients over 65 years of age. Congestion is the main source of symptoms and the leading cause of hospitalization for HF. Furthermore, congestive signs identified in asymptomatic patients are associated with the risk of developing symptomatic HF. The literature supports a multi-modality / integrative evaluation of congestion, combining clinical examination, laboratory results and ultrasound evaluation. The main objective of the CHF-COV study is to identify congestion markers (clinical, biological and ultrasound) quantified during a consultation or day hospitalization for the monitoring of chronic HF that are associated with the risk of all-cause death or hospitalization for acute HF within 24 months after day hospitalization.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
200
Clinical examination (including the EVEREST, ASCEND and Ambrosy scores) centered on congestion will be performed during day hospitalization or consultation
Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds and liver elastography are optional
Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation
Telephone follow-up will be performed 3, 12 and 24 months after visit (during day hospitalization or consultation)
Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
CHRU de Nancy
Vandœuvre-lès-Nancy, France
RECRUITINGCHRU de Nancy
Vandœuvre-lès-Nancy, France
NOT_YET_RECRUITINGRate of death from all causes
composite endpoint : rate of death from all causes or hospitalisation for acute heart failure during 24 months following day hospitalization (with outcome 2)
Time frame: 24 months after day hospitalization or consultation
Rate of hospitalisation for acute heart failure
composite endpoint : rate of death from all causes or hospitalisation for acute heart failure during 24 months following day hospitalization (with outcome 1)
Time frame: 24 months after day hospitalization or consultation
Rate of death from all causes
Time frame: 24 months after day hospitalization or consultation
Rate of hospitalisation for acute heart failure
Time frame: 24 months after day hospitalization or consultation
Rate of hospitalisation for cardiovascular reason
Time frame: 24 months after day hospitalization or consultation
Rate of death from all causes
composite endpoint : Rate of death from all causes or hospitalisation for acute heart failure 24 months after day hospitalization (with outcome 7)
Time frame: 24 months after day hospitalization or consultation
Rate of hospitalisation for acute heart failure
composite endpoint : Rate of death from all causes or hospitalisation for acute heart failure 24 months after day hospitalization (with outcome 6)
Time frame: 24 months after day hospitalization or consultation
Rate of cardiovascular death
Time frame: 24 months after day hospitalization or consultation
NYHA (New York Heart Association) class measured
Time frame: 3, 12 and 24 months after day hospitalization or consulation
Natriuretic peptides
BNP or Nt-Pro BNP
Time frame: At inclusion
Renal function assessed by glomerular filtration rate
Time frame: At inclusion
Plasma volume
Calculated from haemoglobin and haematocrit value
Time frame: At inclusion
Rate of Bilirubin
Time frame: At inclusion
Rate of ASAT
Time frame: At inclusion
Rate of ALAT
Time frame: At inclusion
Rate of V factor
Time frame: At inclusion
Blood potassium concentration
Time frame: At inclusion
Liver elastography value
Measured with Fibroscan®
Time frame: At inclusion
Quality of life assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ)
Time frame: At inclusion and 3, 6 and 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.